About Dharmacon
Dharmacon is a Healthcare company based in Lafayette (United States) founded in 1995, and was acquired by Horizon Discovery in July 2017. It operates as a RNA oligonucleotide synthesis technology is provided for research applications. Dharmacon has raised $5.7 million across 1 funding round from investors including Horizon Discovery, Boulder Ventures and Telegraph Hill Partners. Dharmacon offers products and services including CRISPR Guide RNA, siRNA, Custom Oligonucleotides, and Transfection Reagents. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its legal entity is Revvity Discovery Limited. Its competitors include GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics and 5 more; 9 of its 10 listed competitors have raised funding.
Company details
Dharmacon was founded in 1995 in Lafayette, United States, and operates within the biotechnology sector. Technology for RNA oligonucleotide synthesis is offered, including the 2-ACE RNA method for high-quality synthetic RNA. RNAi-related products and siRNA design services are provided, along with CRISPR Cas9 gene editing tools, custom RNA synthesis, and functional genomic screening capabilities to support various research needs.
- Headquarters Lafayette, United States
- Stage Acquired
- SectorsHealthcare
- Website dharmacon.com
- Social LinkedIn
- Acquired by Horizon Discovery (Jul 2017)
- Legal Name Revvity Discovery Limited
- Total Equity Funding$5.7M (USD)
in 1 rounds
- Latest Funding Round$5.7M (USD), Series A
Aug 2002
- InvestorsHorizon Discovery
& 2 more
- Acquired byHorizon Discovery
(Jul 2017)
Products & Services of Dharmacon
Dharmacon offers a comprehensive portfolio of products and services, including CRISPR Guide RNA, siRNA, Custom Oligonucleotides, and Transfection Reagents.
Reagents for precise genome modification in research.
Tools for RNA interference to silence gene expression.
Tailored RNA and DNA for specific research applications.
Products to deliver nucleic acids into cells efficiently.
Funding Insights of Dharmacon
Dharmacon has successfully raised a total of $5.7M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.7 million completed in August 2002. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.7M
- Total Rounds 1
- Last Round Series A — $5.7M
- First Round $5.7M
(Aug 2002)
- Investors Count 2
All 1 funding rounds of Dharmacon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2002 | $5.7M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in Dharmacon
Dharmacon has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Horizon Discovery, Boulder Ventures and Telegraph Hill Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is offered by Boulder Ventures for innovative companies. | – | boulderventures.com | Boulder, United States | |
Venture capital firm focused on life science, medical device and healthcare companies | – | thpartners.net | San Francisco, United States | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | horizondiscovery.com | Cambridge, United Kingdom |
Investor details for Dharmacon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Dharmacon
3 dated milestones of Dharmacon across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Dharmacon is founded.
- Funding First funding round of $5.7M.
- Exit Acquired by Horizon Discovery.
Competitors of Dharmacon
Dharmacon has 10 listed competitors in our database, 9 of them funded. They include GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of Dharmacon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Dharmacon
Websites that share an audience with Dharmacon (dharmacon.com).
Websites whose visitors overlap most with Dharmacon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ambion.com | 30% | – | – | View details |
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Dharmacon (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Dharmacon
Dharmacon was founded in 1995 and raised its 1st funding round 7 years after it was founded.
Dharmacon is headquartered in Lafayette, United States. It is registered at Lafayette, Louisiana, United States.
Dharmacon is a funded company, having raised a total of $5.7M across 1 funding round to date. The company's 1st funding round was a Series A of $5.7M, raised on Aug 2002.
Dharmacon was founded in 1995 in Lafayette, United States, and operates within the biotechnology sector. Technology for RNA oligonucleotide synthesis is offered, including the 2-ACE RNA method for high-quality synthetic RNA. RNAi-related products and siRNA design services are provided, along with CRISPR Cas9 gene editing tools, custom RNA synthesis, and functional genomic screening capabilities to support various research needs.
Dharmacon's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Dharmacon offers CRISPR Guide RNA, siRNA, Custom Oligonucleotides, and Transfection Reagents.
Dharmacon has 3 investors. Key investors include Horizon Discovery, Boulder Ventures, and Telegraph Hill Partners.
Dharmacon operates through Revvity Discovery Limited.
Yes. Dharmacon was acquired by Horizon Discovery in July 2017.